USD 0.03
(0.0%)
Breakdown | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Operating Cash Flow | 17.14 Thousand | 5.9 Million | -4.3 Million | -12.24 Thousand |
Net Income | 5.95 Million | -31.75 Thousand | 326.67 Thousand | -7.81 Million |
Depreciation & Amortization | - | - | - | - |
Deferred income taxes | - | - | - | - |
Stock-based compensation | - | - | - | - |
Change in working capital | -37.34 Thousand | 5.93 Million | -3.79 Million | 11.19 Thousand |
Other non-cash items | -5.81 Million | -8.71 Million | 5.35 Million | 7.62 Million |
Investing Cash Flow | -20 Thousand | -5.51 Million | -39.21 Thousand | 114.76 Thousand |
Investments in PPE | - | - | - | - |
Acquisitions | - | 3.22 Million | - | - |
Investment purchases | -20 Thousand | - | -39.21 Thousand | - |
Sales/Maturities of investments | - | 3315.56 | - | - |
Other Investing Activities | - | -8.74 Million | - | 114.76 Thousand |
Financing Cash Flow | - | -866.57 Thousand | 4.19 Million | 198.88 Thousand |
Debt repayment | - | -866.57 Thousand | -866.57 Thousand | - |
Dividends payments | - | - | - | - |
Common Stock Repurchased | - | - | - | - |
Common Stock Issuance | - | - | 3.32 Million | - |
Other Financing Activities | - | 1.00 | - | 198.88 Thousand |
Accounts receivables | -86.32 Thousand | 4.95 Million | -3.84 Million | -38.8 Thousand |
Accounts payables | - | - | 1.14 Million | 219.98 Thousand |
Inventory | - | 3.76 Million | -3.49 Million | -15.88 Thousand |
Other working capital | 48.98 Thousand | -2.77 Million | 2.39 Million | -154.1 Thousand |
Cash at beginning of period | 21.26 | 470.11 Thousand | 301.13 Thousand | -272.00 |
Cash at end of period | 25.00 | 21.26 | 470.11 Thousand | 301.13 Thousand |
Capital Expenditure | - | - | - | - |
Effect of forex changes on cash | - | -0.94 | -0.66 | - |
Net cash flow / Change in cash | 3.74 | -470.09 Thousand | 168.98 Thousand | 301.4 Thousand |
Free Cash Flow | 17.14 Thousand | 5.9 Million | -4.3 Million | -12.24 Thousand |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q1 | 2022 FY |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | -837.31 Thousand | -4.96 Million | 5.95 Million | 6.07 Million | -37.62 Thousand | -31.75 Thousand |
Depreciation & Amortization | - | - | - | - | - | - |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | -1745.00 | 34.36 Thousand | -37.34 Thousand | - | 4687.05 | 5.93 Million |
Other non-cash items | 870 Thousand | 4.9 Million | -5.81 Million | -6.04 Million | 32.93 Thousand | -8.71 Million |
Investing Cash Flow | - | - | -20 Thousand | -20 Thousand | - | -5.51 Million |
Investments in PPE | - | - | - | - | - | - |
Acquisitions | - | - | - | - | - | 3.22 Million |
Investment purchases | - | - | -20 Thousand | -20 Thousand | - | - |
Sales/Maturities of investments | - | - | - | - | - | 3315.56 |
Other Investing Activities | - | - | - | - | - | -8.74 Million |
Financing Cash Flow | - | - | - | - | - | -866.57 Thousand |
Debt repayment | - | - | - | - | - | -866.57 Thousand |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | - | - | - | - | - | 1.00 |
Accounts receivables | -30 Thousand | 57.32 Thousand | -86.32 Thousand | - | - | 4.95 Million |
Accounts payables | - | - | - | - | 4687.05 | - |
Inventory | - | - | - | - | - | 3.76 Million |
Other working capital | 28.25 Thousand | -22.96 Thousand | 48.98 Thousand | - | - | -2.77 Million |
Cash at beginning of period | 30.01 Thousand | 25.00 | 21.26 | 30.76 | 52.96 | 470.11 Thousand |
Cash at end of period | 32.24 Thousand | 30.01 Thousand | 25.00 | 25.00 | 27.00 | 21.26 |
Capital Expenditure | - | - | - | - | - | - |
Effect of forex changes on cash | - | - | - | - | - | -0.94 |
Net cash flow / Change in cash | 2227.00 | 29.99 Thousand | 3.74 | -5.76 | -25.96 | -470.09 Thousand |
Free Cash Flow | 944.00 | 27.02 Thousand | 17.14 Thousand | 30.18 Thousand | 4687.05 | 5.9 Million |
PAP
SRP
9696
ONCO
PMREF
005420